Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;68(7):e28979.
doi: 10.1002/pbc.28979. Epub 2021 Apr 12.

Treatment of acute myeloid leukemia in children: A practical perspective

Grace Egan  1 , Yogi Chopra  1 , Stephanie Mourad  2 , Kuang-Yueh Chiang  1 , Johann Hitzler  1   3
Affiliations
Review

Treatment of acute myeloid leukemia in children: A practical perspective

Grace Egan et al. Pediatr Blood Cancer. 2021 Jul.

Abstract

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that requires a multifaceted treatment approach. Although outcomes for low-risk AML have improved significantly over recent decades, high-risk AML continues to be associated with an adverse prognosis. Recent advances in molecular diagnostics, risk stratification, and supportive care have contributed to improvements in outcomes in pediatric AML. Targeted approaches, for example, the use of tyrosine kinase inhibitors to treat FLT3-ITD AML, offer promise and are currently undergoing clinical investigation in pediatric patients. New approaches to hematopoietic stem cell transplantation, including the use of haploidentical donors, are significantly expanding donor options for patients with high-risk AML. This review provides an overview of recent advances in the treatment of pediatric AML that are likely to have clinical impact and reshape the standard of care.

Keywords: HSCT; acute myeloid leukemia; childhood AML; pediatric AML.

PubMed Disclaimer

References

REFERENCES

    1. Smith M, Gloeckler Ries LA, Gurney JG, Ross JA. Leukemia. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
    1. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-1669.
    1. Gibson BES, Sauer MG, Amrolia P. Acute myeloid leukemia in children. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook. Springer International Publishing; 2019:523-530.
    1. Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119(25):5980-5988.
    1. Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015;33(36):4247-4258.

Substances

LinkOut - more resources